I would argue nothing new or unexpected has happened for the last 3 years everything has gone as planned except some of the new products have been delayed.
Sales are great but expected maybe India wasn’t expected 3 years ago but that still hasn’t added real value to sales.
The company continues to kick goals but all have been expected, this is the year that could rerate the company. Expected revenue is about 125-130M very attainable if BARDA revenue can be replicated by say India, a small price increase and a little growth would get PNV to the 125-130 mark. So I do think there is room this year for an outperformance for the first time in many years.
Would like to see an increase in prices for the product as they claim to be the standard of care in many jurisdictions so why not increase it since there is a huge difference between us and the competitors in price and patient outcomes.
I would argue nothing new or unexpected has happened for the...
-
- There are more pages in this discussion • 604 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.99 |
Change
0.010(0.51%) |
Mkt cap ! $1.371B | |||
| Open | High | Low | Value | Volume |
| $1.98 | $1.99 | $1.94 | $2.913M | 1.478M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10216 | $1.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.99 | 3689 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |